Kazia Therapeutics
Sydney, New South Wales, Australia · Biotechnology, Health Care · 9 employees
Kazia Therapeutics is a clinical-stage oncology company developing differentiated therapies for cancers with high unmet need. The company focuses on innovative drug development and is based in Sydney, Australia.
Funding history
- Venture - Series Unknown — $55.3M — Dec 2025
- Seed — $2.1M — Aug 2025
- Seed — $2.0M — Aug 2025
- Seed — $2.1M — Jan 2025
Recent signals
- Jun 02, 2026: Kazia Therapeutics Appoints James Levine as Chief Financial Officer
- Apr 17, 2026: Acquired Kazia Therapeutics acquires QIMR Berghofer's therapy
- Apr 15, 2026: Kazia Therapeutics Appoints Dr. Sudha Rao as Chief Scientific Officer
- Dec 18, 2025: Raised $55.3M in Venture - Series Unknown
- Aug 14, 2025: Raised $2.1M in Seed
- Aug 01, 2025: Raised $2.0M in Seed
- Jan 17, 2025: Raised $2.1M in Seed
See plans & pricing → Track Kazia Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.